Skip Navigation LinksHome > May 2012 - Volume 30 - Issue 5 > Resistant hypertension and obstructive sleep apnea in end-st...
Journal of Hypertension:
doi: 10.1097/HJH.0b013e328352f4c5
Editorial Commentaries

Resistant hypertension and obstructive sleep apnea in end-stage renal disease

Park, Jeaniea,b; Campese, Vito M.c

Free Access
Article Outline
Collapse Box

Author Information

aRenal Division, Department of Medicine, Emory University School of Medicine, Atlanta

bResearch Service Line, Atlanta VA Medical Center, Decatur, Georgia

cNephrology Division, Department of Medicine, Keck School of Medicine at University of Southern California, Los Angeles, California, USA

Correspondence to Dr Vito M. Campese, Nephrology Division, Keck School of Medicine at the University of Southern California, 2020 Zonal Avenue, IRD 804, Los Angeles, CA 90033, USA. Tel: +1 323 226 7337; fax: +1 323 226 5390; e-mail: campese@usc.edu

Patients with end-stage renal disease (ESRD) and nondialysis-dependent chronic kidney disease (CKD) suffer from substantially higher rates of both resistant hypertension and sleep-disordered breathing, both of which are contributing factors to increased cardiovascular mortality in these populations. The prevalence of obstructive sleep apnea (OSA) increases with declining renal function [1], with an estimated prevalence of around 50% in patients with ESRD [2], which is substantially higher than that in the general population. In this issue of the Journal of Hypertension, Abdel-Kader et al.[3] report an observational study that demonstrates a significant association between resistant hypertension and OSA in patients with ESRD. Resistant hypertension was significantly associated with severe OSA in ESRD (odds ratio 7.1), but no significant association was found between the two disorders in CKD patients not on dialysis, or controls without kidney disease.

The connection between hypertension and OSA in the general population has been well described. Patients with OSA are at significantly increased risk of developing hypertension, and the severity of OSA correlates with the level of blood pressure (BP) [2]. The association is even more robust among patients with resistant hypertension and those with severe OSA. In a recent study of 125 consecutive patients with resistant hypertension, nearly two-thirds of the patients had a secondary cause of hypertension, and OSA was by far the most common secondary condition associated with resistant hypertension [4]. Whereas renal parenchymal disease was previously considered the most common identifiable factor associated with resistant hypertension, this study showed that 64% of patients with resistant hypertension had OSA, whereas the prevalence of renal parenchymal disease was 1.6%.

Less is known about the potential relationship between resistant hypertension and OSA in patients with renal disease. As the authors note, it may not be appropriate to extrapolate the findings from the general population in patients with kidney disease, in which the characteristics and pathophysiology of OSA may be different. For instance, ESRD patients with OSA are less likely to report snoring, witnessed apnea during sleep, and morning headaches, which are common clinical features of OSA in the general population [5]. In addition, higher BMI and male sex are not consistently associated with OSA in patients with ESRD [6]. Further, there may be features specific to patients with renal failure, including uremic toxins, metabolic acidosis, inflammation, and volume overload, that predispose to sleep-disordered breathing in ESRD and may be less applicable to the general population [7]. The current study suggests that there is an association between resistant hypertension and OSA in ESRD patients, as there is in the general population, which is an interesting finding that warrants further investigation.

This cross-sectional study does not establish causation or illuminate on mechanisms that may link OSA and resistant hypertension in ESRD. We may speculate that one condition predisposes and contributes to the pathophysiology of the other (i.e. OSA leads to resistant hypertension or resistant hypertension leads to OSA), or a common pathophysiologic mechanism predisposes to both conditions. Three mechanisms that potentially link OSA and resistant hypertension in ESRD include the following: volume excess; aldosterone; and sympathetic nervous system (SNS) overactivation. OSA is characterized by arousals from sleep and transient nocturnal hypoxemia that lead to vasoconstriction, activation of the renin–angiotensin system, and increased renal sodium retention, which contributes to volume overload, an important cause of drug-resistant hypertension in patients with renal failure [8]. In addition, volume overload itself is a major feature of both resistant hypertension and OSA and may contribute to the pathogenesis of OSA due to redistribution of fluid from the legs to the neck and chest in the recumbent position, which in turn leads to increased peripharyngeal edema and upper airway resistance [9]. Friedman et al.[9] found that the severity of OSA was strongly related to the amount of leg fluid volume displaced overnight, and in a separate study, such nocturnal rostral fluid shifts correlated with the severity of OSA in patients with ESRD [10]. Furthermore, greater removal of fluid with dialysis led to improvement in OSA in patients with ESRD [11]. Aldosterone excess likely plays a role in resistant hypertension, OSA, and volume overload in patients with kidney disease. Excess aldosterone is a common feature of drug-resistant hypertension and has been found to correlate with the severity of OSA in patients with resistant hypertension [2]. Aldosterone, in turn, may contribute to the pathogenesis of OSA via fluid retention and may explain the variability in BP-lowering effect of continuous positive airway pressure (CPAP) therapy in patients with resistant hypertension.

Finally, SNS overactivation is likely a key mechanism by which OSA contributes to hypertension, as well as the preexisting abnormality that leads to both resistant hypertension and OSA in patients with ESRD. Multiple studies have shown that muscle sympathetic nerve activity (MSNA) is chronically elevated in patients with OSA [12–14] and is improved with nocturnal CPAP [15]. The mechanisms by which OSA leads to chronic SNS overactivation are unclear, but may include chronic activation of sympatho-excitatory peripheral chemoreceptors induced by chronic intermittent hypoxemia [14,16]. When chemoreceptors were deactivated by administration of 100% oxygen, MSNA and BP decreased in patients with OSA, but not in controls, suggesting tonic chemoreflex activation of SNS outflow in OSA. SNS overactivity, in turn, contributes to resistant hypertension via vasoconstriction, activation of the renin–angiotensin system, volume retention, endothelial dysfunction, oxidative stress, and vascular stiffening. Although the prevailing theory had been that chronic intermittent hypoxemia causes sustained increases in SNS activity, newer evidence is emerging that SNS overactivity itself may be a cause of OSA, rather than a consequence. Renal denervation therapy, in which both afferent and efferent renal nerves are disrupted, is accompanied by a profound reduction in central SNS outflow and was found to result in BP reduction and improvement in OSA severity in patients with resistant hypertension and OSA [17]. ESRD and CKD patients have chronically elevated SNS activity at baseline due to multiple mechanisms, including afferent renal nerve activation within the diseased kidneys, which increase cardiovascular risk and contribute to resistant hypertension in these patients [18,19]. Thus, SNS overactivity may be the initiating mechanism that perpetuates both resistant hypertension and OSA in patients with renal failure.

One puzzling aspect of the current study is the lack of association of resistant hypertension and OSA in CKD patients and controls, which was most likely due to small sample size. Whether these associations exist in larger studies, and whether interventions to improve SNS activity or volume status improve resistant hypertension and OSA in patients with kidney disease, remains to be tested.

Back to Top | Article Outline

ACKNOWLEDGEMENTS

J.P. is supported by NIH grant K23HL098744, Amgen Nephrology Junior Faculty Award, and the Atlanta Research and Education Foundation.

Back to Top | Article Outline
Conflicts of interest

There are no conflicts of interest.

Back to Top | Article Outline

REFERENCES

1. Nicholl DM, Ahmed SB, Loewen AH, Hemmelgarn BR, Sola DY, Beecroft JM, et al. Declining kidney function increases the prevalence of sleep apnea and nocturnal hypoxia. Chest 2012 [Epub ahead of print].

2. Dudenbostel T, Calhoun DA. Resistant hypertension, obstructive sleep apnoea and aldosterone. J Hum Hypertens 2011 [Epub ahead of print].

3. Abdel-Kader K, Dohar S, Shah N, Jambh M, Reis SE, Strollo P, et al. Resistant hypertension and obstructive sleep apnea in the setting of kidney disease. J Hypertens 2012; 30:960–966.

4. Pedrosa RP, Drager LF, Gonzaga CC, Sousa MG, de Paula LK, Amaro AC, et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension 2011; 58:811–817.

5. Beecroft JM, Pierratos A, Hanly PJ. Clinical presentation of obstructive sleep apnea in patients with end-stage renal disease. J Clin Sleep Med 2008; 5:115–121.

6. Perl J, Unruh ML, Chan CT. Sleep disorders in end-stage renal disease: ’markers of inadequate dialysis’? Kidney Int 2006; 70:1687–1693.

7. Tada T, Kusano KF, Ogawa A, Iwasaki J, Sakuragi S, Kusano I, et al. The predictors of central and obstructive sleep apnoea in haemodialysis patients. Nephrol Dial Transplant 2007; 22:1190–1197.

8. Tsioufis C, Kordalis A, Flessas D, Anastasopoulos I, Tsiachris D, Papademetriou V, Stefanadis C. Pathophysiology of resistant hypertension: the role of sympathetic nervous system. Int J Hypertens 2011; 2011:642416.

9. Friedman O, Bradley TD, Chan CT, Parkes R, Logan AG. Relationship between overnight rostral fluid shift and obstructive sleep apnea in drug-resistant hypertension. Hypertension 2010; 56:1077–1082.

10. Elias RM, Bradley TD, Kasai T, Motwani SS, Chan CT. Rostral overnight fluid shift in end-stage renal disease: relationship with obstructive sleep apnea. Nephrol Dial Transplant 2011 [Epub ahead of print].

11. Hanly PJ, Pierratos A. Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis. N Engl J Med 2001; 344:102–107.

12. Grassi G, Facchini A, Trevano FQ, Dell’Oro R, Arenare F, Tana F, et al. Obstructive sleep apnea-dependent and -independent adrenergic activation in obesity. Hypertension 2005; 46:321–325.

13. Narkiewicz K, van de Borne PJ, Cooley RL, Dyken ME, Somers VK. Sympathetic activity in obese subjects with and without obstructive sleep apnea. Circulation 1998; 98:772–776.

14. Narkiewicz K, van de Borne PJ, Montano N, Dyken ME, Phillips BG, Somers VK. Contribution of tonic chemoreflex activation to sympathetic activity and blood pressure in patients with obstructive sleep apnea. Circulation 1998; 97:943–945.

15. Narkiewicz K, Kato M, Phillips BG, Pesek CA, Davison DE, Somers VK. Nocturnal continuous positive airway pressure decreases daytime sympathetic traffic in obstructive sleep apnea. Circulation 1999; 100:2332–2335.

16. Narkiewicz K, van de Borne PJ, Pesek CA, Dyken ME, Montano N, Somers VK. Selective potentiation of peripheral chemoreflex sensitivity in obstructive sleep apnea. Circulation 1999; 99:1183–1189.

17. Witkowski A, Prejbisz A, Florczak E, Kądziela J, Śliwiński P, Bieleń P, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 2011; 58:559–565.

18. Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995; 25 (Pt 2):878–882.

19. Park J, Campese VM, Middlekauff HR. Exercise pressor reflex in humans with end-stage renal disease. Am J Physiol Regul Integr Comp Physiol 2008; 295:R1188–R1194.

© 2012 Lippincott Williams & Wilkins, Inc.

Login